These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 25397536)

  • 1. Boosted lopinavir vs boosted atazanavir in patients failing a NNRTI first line regimen in an urban clinic in Kampala.
    Laker E; Mambule I; Nalwanga D; Musaazi J; Kiragga A; Parkes-Ratanshi R
    J Int AIDS Soc; 2014; 17(4 Suppl 3):19792. PubMed ID: 25397536
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of nucleoside reverse transcriptase inhibitor backbone on the efficacy of first-line boosted highly active antiretroviral therapy based on protease inhibitors: meta-regression analysis of 12 clinical trials in 5168 patients.
    Hill A; Sawyer W
    HIV Med; 2009 Oct; 10(9):527-35. PubMed ID: 19785663
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunological and Virological Outcomes of Patients Switched from LPV/r to ATV/r-Containing Second- Line Regimens.
    Akanmu AS; Adeyemo T; Lesi F; Bello FO; Okwuegbuna K; Oloko K; Awolola A; Ogunsola FT; Okonkwo P; Kanki PJ
    Curr HIV Res; 2015; 13(3):176-83. PubMed ID: 25986368
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized comparison of second-line lopinavir/ritonavir monotherapy versus tenofovir/lamivudine/lopinavir/ritonavir in patients failing NNRTI regimens: the HIV STAR study.
    Bunupuradah T; Chetchotisakd P; Ananworanich J; Munsakul W; Jirajariyavej S; Kantipong P; Prasithsirikul W; Sungkanuparph S; Bowonwatanuwong C; Klinbuayaem V; Kerr SJ; Sophonphan J; Bhakeecheep S; Hirschel B; Ruxrungtham K;
    Antivir Ther; 2012; 17(7):1351-61. PubMed ID: 23075703
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Boosted or unboosted atazanavir as a simplification of lopinavir/ritonavir-containing regimens.
    Castagna A; Galli L; Gianotti N; Torti C; Antinori A; Maserati R; d'Arminio Monforte A; Quiros-Roldan E; Salpietro S; Lazzarin A
    New Microbiol; 2013 Jul; 36(3):239-49. PubMed ID: 23912865
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An observational comparison of first-line combination antiretroviral treatment (cART) with 2NRTI and ATV/r or DRV/r in HIV-infected patients in Italy.
    Cozzi-Lepri A; Antinori A; Bonora S; Cingolani A; Cassola G; Angarano G; Vullo V; Mussini C; Gori A; Maggiolo F; Castagna A;
    J Int AIDS Soc; 2014; 17(4 Suppl 3):19771. PubMed ID: 25397515
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Switching to boosted protease inhibitor plus a second antiretroviral drug (dual therapy) for treatment simplification: a multicenter analysis.
    Zaccarelli M; Fabbiani M; Pinnetti C; Borghi V; Giannetti A; Sterrantino G; Lorenzini P; Latini A; Loiacono L; Colafigli M; Ammassari A; D'Ettorre G; Plazzi M; Di Giambenedetto S; Antinori A
    J Int AIDS Soc; 2014; 17(4 Suppl 3):19802. PubMed ID: 25397546
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HIV-1 genital shedding in HIV-infected patients randomized to second-line lopinavir/ritonavir monotherapy versus tenofovir/lamivudine/lopinavir/ritonavir.
    Bunupuradah T; Bowonwattanuwong C; Jirajariyavej S; Munsakul W; Klinbuayaem V; Sophonphan J; Mahanontharit A; Hirschel B; Ruxrungtham K; Ananworanich J;
    Antivir Ther; 2014; 19(6):579-86. PubMed ID: 24464590
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Switching to tenofovir/emtricitabine from abacavir/lamivudine in HIV-infected adults with raised cholesterol: effect on lipid profiles.
    Behrens G; Maserati R; Rieger A; Domingo P; Abel F; Wang H; Pearce G
    Antivir Ther; 2012; 17(6):1011-20. PubMed ID: 22910324
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of associations and development of atazanavir resistance after unplanned treatment interruptions.
    Tinago W; O'Halloran JA; O'Halloran RM; Macken A; Lambert JS; Sheehan GJ; Mallon PW
    HIV Med; 2014 Apr; 15(4):224-32. PubMed ID: 24215370
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Less frequent follow-up in routine care than in trials does not impact resistance selection in patients failing DRV/r or ATV/r first line treatment.
    Marcelin AG; Charpentier C; Wirden M; Descamps D; Calvez V
    J Int AIDS Soc; 2014; 17(4 Suppl 3):19744. PubMed ID: 25397489
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Salvage therapy with atazanavir/ritonavir combined to tenofovir in HIV-infected patients with multiple treatment failures: randomized ANRS 107 trial.
    Piketty C; Gérard L; Chazallon C; Marcelin AG; Clavel F; Taburet AM; Calvez V; Madelaine-Chambrin I; Molina JM; Aboulker JP; Girard PM;
    Antivir Ther; 2006; 11(2):213-21. PubMed ID: 16640102
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized trial of DRV/r or LPV/r QD monotherapy vs maintaining a PI/r-based antiretroviral regimen in persons with suppressed HIV replication.
    Pinnetti C; Lorenzini P; Cozzi-Lepri A; Sandrine O; Tommasi C; Zaccarelli M; Perno CF; Capobianchi MR; Girardi E; Antinori A; Ammassari A
    J Int AIDS Soc; 2014; 17(4 Suppl 3):19809. PubMed ID: 25397553
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lipid changes in HIV-patients switching to the coformulated single tablet FTC/RPV/TDF (Eviplera®). Efficacy and safety analysis. GeSida Study 8114.
    Pérez-Hernández IA; Palacios R; Mayorga M; González-Doménech CM; Castaño M; Rivero A; Del Arco A; Lozano F; Santos J
    J Int AIDS Soc; 2014; 17(4 Suppl 3):19795. PubMed ID: 25397539
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Factors involved in treatment durability and immunological recovery in a cohort of HIV-positive patients receiving atazanavir-based regimens.
    Giacomelli A; Oreni L; Franzetti M; Di Cristo V; Vergani B; Morosi M; Colella E; Galli M; Rusconi S
    J Int AIDS Soc; 2014; 17(4 Suppl 3):19830. PubMed ID: 25397574
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential effects of efavirenz, lopinavir/r, and atazanavir/r on the initial viral decay rate in treatment naïve HIV-1-infected patients.
    Edén A; Andersson LM; Andersson O; Flamholc L; Josephson F; Nilsson S; Ormaasen V; Svedhem V; Säll C; Sönnerborg A; Tunbäck P; Gisslén M
    AIDS Res Hum Retroviruses; 2010 May; 26(5):533-40. PubMed ID: 20455766
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost effectiveness of atazanavir-ritonavir versus lopinavir-ritonavir in treatment-naïve human immunodeficiency virus-infected patients in the United States.
    Broder MS; Chang EY; Bentley TG; Juday T; Uy J
    J Med Econ; 2011; 14(2):167-78. PubMed ID: 21288058
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost/efficacy analysis of preferred Spanish AIDS study group regimens and the dual therapy with LPV/r+3TC for initial ART in HIV infected adults.
    Gatell JM; Arribas JR; Lázaro P; Blasco A
    J Int AIDS Soc; 2014; 17(4 Suppl 3):19603. PubMed ID: 25394107
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 96-week comparison of once-daily atazanavir/ritonavir and twice-daily lopinavir/ritonavir in patients with multiple virologic failures.
    Johnson M; Grinsztejn B; Rodriguez C; Coco J; DeJesus E; Lazzarin A; Lichtenstein K; Wirtz V; Rightmire A; Odeshoo L; McLaren C
    AIDS; 2006 Mar; 20(5):711-8. PubMed ID: 16514301
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exploratory Analysis for the Evaluation of Estimated Glomerular Filtration Rate, Cholesterol and Triglycerides after Switching from Tenofovir/Emtricitabine plus Atazanavir/Ritonavir (ATV/r) to Abacavir/Lamivudine plus ATV/r in Patients with Preserved Renal Function.
    Postorino MC; Quiros-Roldan E; Maggiolo F; Di Giambenedetto S; Ladisa N; Lapadula G; Lorenzotti S; Sighinolfi L; Castelnuovo F; Di Pietro M; Gotti D; Mazzini N; Torti C;
    Open AIDS J; 2016; 10():136-43. PubMed ID: 27563366
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.